How many drugs treat Streptococcal tonsillitis?

Drug Landscape tracks 10 marketed treatments for Streptococcal tonsillitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/streptococcal-tonsillitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Streptococcal tonsillitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Streptococcal tonsillitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Streptococcal tonsillitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cefditoren Pivoxyl	CEFDITOREN PIVOXIL	Vansen Pharma	Cephalosporin Antibacterial		2001-01-01
Cedax	ceftibuten	Burke Therap	Cephalosporin Antibacterial		1995-01-01
Zithromax	azithromycin	Pfizer Inc.	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01
Biaxin	clarithromycin	Generic (originally Abbott/AbbVie)	Macrolide Antimicrobial [EPC]	Potassium voltage-gated channel subfamily H member 2	1991-10-31
Cefzil	cefprozil	Teva Pharmaceuticals USA	Cephalosporin Antibacterial [EPC]		1991-01-01
Ceftin	CEFUROXIME AXETIL	GSK	Cephalosporin Antibacterial		1987-01-01
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Cefradex	cefradine	Bristol-Myers Squibb	cefradine	Matrix metalloproteinase-9	1974-01-01
Amoxil	amoxicillin	Generic (originally Beecham/GSK)	Aminopenicillin (Beta-lactam antibiotic)	5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C	1972-01-01
Keflex	cefalexin	Shionogi	Cephalosporin Antibacterial	Solute carrier family 15 member 2	1971-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 7 drugs in Streptococcal tonsillitis
GSK · 2 drugs in Streptococcal tonsillitis
Bristol-Myers Squibb · 2 drugs in Streptococcal tonsillitis
Generic (originally Beecham/GSK) · 1 drug in Streptococcal tonsillitis
Karlstad University · 1 drug in Streptococcal tonsillitis
Katarina Hedin · 1 drug in Streptococcal tonsillitis
King George's Medical University · 1 drug in Streptococcal tonsillitis
Pfizer · 1 drug in Streptococcal tonsillitis
Pfizer Inc. · 1 drug in Streptococcal tonsillitis
Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. · 1 drug in Streptococcal tonsillitis
Shionogi · 1 drug in Streptococcal tonsillitis
Sohag University · 1 drug in Streptococcal tonsillitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Streptococcal tonsillitis:

Cite this brief

Drug Landscape (2026). Streptococcal tonsillitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/streptococcal-tonsillitis. Accessed 2026-06-10.

Streptococcal tonsillitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing